• Adel S Alharbi, Mohamed Alzahrani, Abdulrahman N Alodayani, Mohamed Y Alhindi, Saleh Alharbi, and Abdulrahman Alnemri.
• From the Department of Pediatrics (Alharbi A, Alodayani), Prince Sultan Military Medical City; from the Department of Pediatrics (Alzahrani), Security Forces Hospital; from the Pediatrics Department (Alnemri), College of Medicine, King Saud University, Riyadh; from the Department of Pediatrics (Alhindi), King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard; from the Department of Pediatrics (Alharbi S), Dr. Soliman Fakeeh Hospital, Jeddah; and from the Department of Pediatrics (Alharbi S), Umm Al-Qura University, Mecca, Kingdom of Saudi Arabia.
• Saudi Med J. 2021 Apr 1; 42 (4): 355-362.

AbstractRespiratory syncytial virus (RSV) is the most common cause of bronchiolitis and viral pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of RSV is 23.5% in pediatric patients with acute lower respiratory tract illness. Coronavirus disease (COVID-19) poses critical public health and socioeconomic challenges in KSA. The Saudi Pediatric Pulmonology Association (SPPA), a subsidiary of the Saudi Thoracic Society (STS), developed a task force to determine the potential challenges and barriers to the RSV immunoprophylaxis program during the era of COVID-19 and to compose a practical, nationwide, and multidisciplinary approach to address these challenges. Some of the recommendations to manage these challenges include increasing the number of RSV immunoprophylaxis clinics, drive-thru visits, home-care services, and swift referrals to the RSV immunoprophylaxis program specialists. Additional training is required for healthcare personnel to add RSV immunoprophylaxis to the regular immunization schedule.Copyright: © Saudi Medical Journal.

30 keywords...

hide…